Omnicom Health Group, the largest healthcare marketing and communications group in the world and part of Omnicom Group Inc. (NYSE: OMC), announced the acquisition of Archbow Consulting.
If you are not happy with the results below please do another search
50 search results for:
Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.
India’s new coronavirus infections hit a record level on April 14 with Mumbai set to be locked down at midnight, but hundreds of thousands of pilgrims still thronged to a religious festival in the north of the country.
Brazil’s richest and most populous state, Sao Paulo, warned its ability to care for seriously ill Covid-19 patients was on the verge of collapse as it ran perilously low on key drugs, according to a letter to the federal government seen by the Folha de Sao Paulo newspaper.
The first study to directly compare immune reactions between Pfizer’s and AstraZeneca’s Covid-19 vaccines found strong and broadly similar antibody responses in over-80-year-olds after a first dose of either shot, scientists said on April 14.
Shanghai, China-based SciNeuro Pharmaceuticals and U.S.-based Eli Lilly inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China
A U.S. health advisory panel on April 14 is set to review six reported cases of rare blood clots in women who received Johnson & Johnson’s Covid-19 vaccine one day after federal regulators paused the use of the shot to assess the issue.
Havas Health & You announced their continued investment in Customer Experience and Innovation with several leadership changes.
AstraZeneca Plc said on April 14 that China’s health regulator expanded the use of Tagrisso, the British drugmaker’s lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage.
The U.S. Food and Drug Administration granted accelerated approval of Gilead Sciences Inc.’s Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor.